लोड हो रहा है...

The promise of anti-ErbB3 monoclonals as new cancer therapeutics

In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node for the progression of several cancer types. From the mechanistic standpoint the intracellular region of this receptor is rich of tyrosine residues that, upon phosphorylation, become high affinity binding sites...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Aurisicchio, Luigi, Marra, Emanuele, Roscilli, Giuseppe, Mancini, Rita, Ciliberto, Gennaro
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2012
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3478453/
https://ncbi.nlm.nih.gov/pubmed/22889873
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!